Confronto

Amycretin vs. Semaglutid

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Metabolico

N. CAS

nessun dato

910463-68-2

Peso molecolare

nessun dato

4113.6 g/mol

Emivita

nessun dato

165 h

Sequenza

nessun dato

modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-Linker

Meccanismo d'azione

Amycretin

Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.

Semaglutid

Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Amycretin	Semaglutid
Svizzera	—	Su prescrizione
Germania	Non approvato	Su prescrizione
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Amycretin and Semaglutid?: Amycretin is classified as "Metabolico", while Semaglutid is classified as "Metabolico". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Amycretin or Semaglutid?: The highest available evidence level is "RCT sull'uomo" for Amycretin and "RCT sull'uomo" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Amycretin and Semaglutid in Germany and the United States?: Germania: Amycretin — Non approvato, Semaglutid — Su prescrizione. Stati Uniti: Amycretin — Non approvato, Semaglutid — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Amycretin

Semaglutid

Svizzera

—

Su prescrizione

Germania

Non approvato

Su prescrizione

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between Amycretin and Semaglutid?

Amycretin is classified as "Metabolico", while Semaglutid is classified as "Metabolico". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Amycretin or Semaglutid?

The highest available evidence level is "RCT sull'uomo" for Amycretin and "RCT sull'uomo" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Amycretin and Semaglutid in Germany and the United States?

Germania: Amycretin — Non approvato, Semaglutid — Su prescrizione. Stati Uniti: Amycretin — Non approvato, Semaglutid — Su prescrizione. These are factual summaries with source and review date on the individual pages.